| Literature DB >> 35893863 |
Abstract
Breastfeeding (BF) is the most natural mode of nutrition. Its beneficial effect has been revealed in terms of both the neonatal period and those of lifelong effects. However, as for protection against allergy, there is not enough data. In the current narrative review, the literature within the last five years from clinical trials and population-based studies on breastfeeding and allergy from different aspects was explored. The aim of this review was to explain how different factors could contribute to the overall effect of BF. Special consideration was given to accompanying exposure to cow milk, supplement use, the introduction of solid foods, microbiota changes, and the epigenetic function of BF. Those factors seem to be modifying the impact of BF. We also identified studies regarding BF in atopic mothers, with SCFA as a main player explaining differences according to this status.Entities:
Keywords: breastfeeding; epigenetics; food allergy; maternal atopy
Mesh:
Substances:
Year: 2022 PMID: 35893863 PMCID: PMC9331378 DOI: 10.3390/nu14153011
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Summary of the recent literature regarding breastfeeding (BF) and allergy outcomes.
| Intervention or Observation | Age of Intervention or Observation | Type of Study | Outcome | Age of Outcome | Number of Participants | Effect of BF on Outcome | Limitations | Conclusion | |
|---|---|---|---|---|---|---|---|---|---|
| Cow milk exposure | |||||||||
| Urashima M, 2019 [ | Avoiding supplementation with cow milk | 1 day–5 months | RCT | Sensitization to cow milk | 2 years | 312 | RR 0.52 (0.34–0.81) | Amino acid formula in avoiding CM arm and switching to CM arm after 3 days | Sensitization to cow milk is preventable by avoiding CMF for at least 3 days of life |
| Sakihara T, 2021 [ | Early introduction and daily infant CMF | 1–2 months | RCT | CMA by OFC | 6 months | 504 | RR 0.12 (0.01–0.5) | Soya-based formula in no CMF arm | Daily ingestion of CMF prevents CMA development |
| BF effect as only exposure | |||||||||
| Ek WE, 2018 [ | BF yes or not | time of BF | Cohort | Self-reported asthma | 38–73 years | 336,364 | Asthma | Wide time interval, population with different environmental exposure and cultural behaviors | BF is associated with an increased risk for hay fever and eczema, |
| Flohr C, 2018 [ | BF promotion | birth | Cluster RT | Spirometry | 16 years | 17,046 | Eczema | Allocation was not blinded | BF reduces eczema risk but not asthma |
| Filipiak-Pirttroff B, 2018 [ | Exclusive BF for 4 month or supplementation with randomized formula | birth | RCT | Asthma | 1, 2, 3, 4, 6, 10, and 15 years | 5991 | non-risk non-intervention | Recall bias in non-intervention group | In the non-intervention non-risk cohort—BF showed no effect on eczema and asthma, but a risk reduction for allergic rhinitis |
| Hu Y, 2021 [ | Duration of BF | 6–11 years | Population based | Asthma | 6–11 years | 10,464 | Asthma | Self-reported allergy | BF > 6 months is inversely associated with childhood asthma and allergic diseases and modifies the risks of parental allergy and Cesarean section |
| BF and microbiome composition | |||||||||
| Sordillo JE, 2017 [ | Infant gut microbiome | Pregnancy—vitamin D | RCT | Gut microbiome composition | 3–6 months stool | 333 | beta | High-risk infants, | Ethnicity, mode of delivery, BF, and cord blood vitamin D levels are associated with infant gut microbiome composition |
| Savage JH, 2018 [ | Intestinal microbiome in breastfed high-risk infants (atopic mother or father) | pregnancy | RCT | Microbial composition | 3–6 months | 323 | Bifidobacterium | Included only high-risk infants | BF is dietary factor independently associated with microbiome composition |
| Korpela K, 2018 [ | Probiotic supplementation with BF | pregnancy and infancy until 6 month | RCT | Intestinal microbiota composition | 3 months | 428 | NA | Studying microbiota only, not proving any impact on allergy risk | At least partial breastfeeding together with probiotic supplementation might correct unfavorable changes in microbiota composition (possibly related to allergy risk) caused by antibiotics and cesarean birth |
| Lee-Sarwar KA, 2019 [ | Intestinal microbiome | pregnancy | RCT | Asthma at 3 y | 3 years | 361 | beta 0.02 | Parent reported asthma | Asthma-associated intestinal |
| Supplement use with BF | |||||||||
| Sprenger N, 2017 [ | FUT2-HMO measurement in the placebo group from supplementation with probiotics and prebiotics trial | Mean 2.6 day | RCT | Allergy | 2 years 5 years | 266 | beta | High-risk infants | A lower risk of manifesting IgE-associated eczema at 2 years, but not 5 years, when fed breast milk with FUT2-HMO |
| Wickens K, 2018 [ | Supplementation with either Lactobacillus rhamnosus HN001 | Mothers from 35 weeks of pregnancy—6 month Postpartum; children 1 day–2 year | RCT | Eczema | 10 years | 298 | 12 months prevalence | Study not directed at BF, mixed effect of maternal and child’s diet supplementation | HN001 supplementation is associated with a significant reduction in hay fever, eczema, wheeze, and atopic sensitization |
| Henrick BM, 2021 [ | Supplementation with B.infantis EVC001 | 7–28 day | CT | Metagenomics profile | 1–6 month | 208 Sweden | NA | No intestinal tissue studied | Infants colonized early in life with Bifidobacterium species are less likely to develop immune-mediated diseases |
| Solid food introduction | |||||||||
| Pitt TJ, 2018 [ | Peanut introduction before 12 month | Infancy and time of BF | Cohort | Peanut sensitization | 7 years | 545 | OR 0.08 | No data on environmental peanut exposure and peanut exposure during pregnancy | Maternal peanut consumption while breastfeeding paired with direct introduction is associated with a lower risk of peanut sensitization |
| Marrs T, 2021 [ | Solid food | 3 months | RCT | Intestinal microbiota | 6 months 12 months | 288 | NA | No data before 3 month | Introduction of allergenic solids from age 3 months alongside breastfeeding is associated with maturation of the gut microbiota |
| Epigenetic effect of BF | |||||||||
| Mallisetty Y, 2020 [ | Epigenetics of BF | Time of BF | Cohort IOWBC | Methylation in blood | birth | 201 | NA | Relatively small sample size | 87 CpGs were identified as DM, |
| Atopic mothers | |||||||||
| Stinson LF, 2020 [ | SCFA composition measurement in BM from atopic and non-atopic mothers | 1 month | Cohort | SCFA composition | 1 month | 109 | NA | No allergy phenotype in children studied | Atopic mothers had significantly lower concentrations of acetate and butyrate than non-atopic mothers |
The table contains data from clinical trials (CT), randomized clinical trials (RCT), and population-based (cohort) studies. RR—relative risk, OR—odds ratio, beta—estimate in the regression model, BM—breast milk, CMF—cow milk formula, CM—cow milk, CMA—cow milk allergy, OFC—oral food challenge, SCFA—short fatty chain acids, EBF—exclusively breastfed, EFF—exclusively formula fed, VDAART—Vitamin D Atenatal Asthma Reduction Trial, FUT2—Fucosyltransferase 2 gene, IOWBC—The Isle Of Wight Whole Population Birth Cohort, HMO—human milk oligosaccharides, DM—differentially methylated NA—not applicable.
Figure 1The figure illustrates the epigenetic effect of BF.